BRIEF published on 10/30/2024 at 17:50, 1 year 1 month ago Median Technologies and AI in lung cancer screening Artificial Intelligence Medical Technologies Lung Cancer Webconférence 2024 Medical Screening
BRIEF published on 10/07/2024 at 17:50, 1 year 1 month ago Status of voting rights and capital of Median Technologies as of September 30, 2024 Voting Rights Capital Actions Median Technologies September 30, 2024
BRIEF published on 09/06/2024 at 17:50, 1 year 2 months ago Modification of the rights attached to the categories of shares of Median Technologies Voting Rights Capital Actions Median Technologies Modification Of Rights
PRESS RELEASE published on 09/06/2024 at 17:45, 1 year 2 months ago Changes in the rights attaching to the classes of shares or securities Median Technologies discloses total voting rights and shares as of August 31, 2024, in accordance with regulatory requirements. Company uses AI for cancer diagnoses and treatments globally Voting Rights Shares AI Median Technologies Cancer Diagnosis
BRIEF published on 09/04/2024 at 17:50, 1 year 3 months ago Median Technologies: Promising results for the diagnosis of lung cancer Artificial Intelligence Median Technologies Lung Cancer Eyonis™ LCS Pivotal Study
PRESS RELEASE published on 09/04/2024 at 17:45, 1 year 3 months ago Inside Information / Other news releases Median Technologies to share positive pivotal data for eyonis™ LCS diagnostic software at IASLC 2024 World Conference on Lung Cancer. eyonis™ LCS achieves high accuracy in detecting lung cancer Median Technologies Lung Cancer Eyonis LCS IASLC 2024 Diagnostic Software
BRIEF published on 08/29/2024 at 17:50, 1 year 3 months ago Median Technologies: eyonis achieves REALITY study objectives Screening Median Technologies Lung Cancer Eyonis™ LCS AUC
BRIEF published on 07/18/2024 at 18:01, 1 year 4 months ago Median Technologies unveils half-year results and strategic advances Artificial Intelligence Turnover Backlog ICRO Eyonis™ LCS
PRESS RELEASE published on 07/18/2024 at 17:56, 1 year 4 months ago Inside Information / News release on accounts, results Median Technologies reports record iCRO backlog and eyonis™ LCS on-track for pivotal study readout in August. Revenue at €10.9 million, cash at €16 million. CEO to provide update via webcast on July 24, 2024 Revenue Growth Median Technologies ICRO Eyonis LCS Pivotal Study
BRIEF published on 06/07/2024 at 17:50, 1 year 5 months ago Changes in Shareholder Voting Rights at Median Technologies Share Capital Voting Rights French Regulations Median Technologies Non-voting Shares
Published on 12/05/2025 at 02:35, 7 hours 23 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 8 hours 58 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 10 hours 53 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 10 hours 58 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 09:40, 18 minutes ago Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 28 minutes ago REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 09:05, 53 minutes ago Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 08:45, 1 hour 13 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 15 hours 58 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 16 hours 13 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 16 hours 14 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 2 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
